BioSpace News Archive

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be accompanying Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Lab (“CRL”) in a webinar titled “A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19" on Thursday, April 29 at 2:00 PM EDT.

Valted Seq, a biotechnology company focused on the discovery of neurodegenerative pathways and biomarkers to inform and accelerate development of new therapeutics and diagnostics, today announced an exclusive right to evaluate technology from Johns Hopkins University for development of poly(ADP-ribose) (PAR) and c-Abl pathway biomarker assays to enable diagnosis and management of neurodegenerative diseases.

Scientists investigate if City of Hope’s natural supplement derived from white button mushroom could lower prostate-specific antigen levels, an indicator of prostate cancer.

Valo Health, LLC (Valo), the technology company that is using human-centric data, machine learning computation and life science expertise to transform and accelerate the drug discovery and development process, today announced that David Berry , Ph.D., founder and Chief Executive Officer of Valo will participate in a panel discussion

The American Orthotic and Prosthetic Association, founded in 1917, represents more than 2,000 patient care facilities and businesses that manufacture, distribute, design, fabricate, fit, and supervise the use of orthoses and prostheses.

Collaborative mice study with UC San Diego to study brain development from embryo to old age

Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels.

The University of Utah, ARUP Laboratories, and Techcyte Inc. announced that they have formed a partnership to develop NanoSpot.AI, a less than five-minute, easy-to-administer SARS-CoV-2 antibody test.

The company’s aim is to obtain regulatory approval and clinical laboratory licenses to be fully operational in early 2022 and start offering its metabolomics biomarker panel for early lung cancer detection to physicians initially across the Province of Quebec.

Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com.